Esperion Thera

ESPR NASDAQ
43.16
-1.03
-2.33%
Opening 10:46 07/19 EDT
Open
44.13
Prev Close
44.19
High
44.63
Low
43.02
Volume
112.26K
Avg Vol (3M)
510.37K
52 Week High
60.99
52 Week Low
36.06
% Turnover
0.42%
Market Cap
1.16B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Esperion Thera ESPR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
MORE >

Recently

Name
Price
%Change